Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a potential biomarker and therapeutic target

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Thomas Oellerich, Constanze Schneider, Dominique Thomas, Kirsten M. Knecht, Olga Buzovetsky, Lars Kaderali, Christoph Schliemann, Hanibal Bohnenberger, Linus Angenendt, Wolfgang Hartmann, Eva Wardelmann, Tamara Rothenburger, Sebastian Mohr, Sebastian Scheich, Federico Comoglio, Anne Wilke, Philipp Ströbel, Hubert Serve, Martin Michaelis, Nerea Ferreirós, Gerd Geisslinger, Yong Xiong, Oliver T. Keppler, Jindrich Cinatl
Format: article
Langue:EN
Publié: Nature Portfolio 2019
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/95a48b4cc3c74d05b739c67d702815e2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a potential biomarker and therapeutic target

Documents similaires